Corcept names Justin Gunn to succeed retiring endocrinology president Sean Maduck
Sean Maduck steps down as President of Corcept's Endocrinology division effective October 1, 2026, with Justin Gunn taking over the role.
SEC filing
Latest
4 stories
Yesterday
Friday, September 25
Corcept's ROSELLA Phase 3 posts results for relacorilant plus nab-paclitaxel in ovarian cancer
Wednesday, September 23
Wednesday, July 29
Corcept raises 2026 revenue guidance to $1.1-$1.2 billion after Lifyorli launch quarter
The company reported second-quarter revenue of $256.1 million, driven by Korlym and a new Lifyorli launch, and outlined multiple near-term regulatory and trial milestones.
SEC filing